Indication
Cell Therapy
2 clinical trials
2 products
Clinical trial
A Phase 1/2, Open-Label, First-in-human, Multiple Ascending Dose Multicenter Study of MT-101 in Subjects With CD5+ Relapsed/Refractory T Cell LymphomaStatus: , Estimated PCD: 2024-11-01
Clinical trial
Muscle Cell Mediated Therapy for Stress Urinary Incontinence: An Investigation of the Safety of 4 Different Doses of Autologous Muscle Derived Cells.Status: Completed, Estimated PCD: 2011-11-02
Product
MT-101